First-in-human implantation of the Topaz transcatheter tricuspid valve replacement system

DOI: 10.4244/EIJ-D-22-00277

Emmanuel Teiger
Emmanuel Teiger1, MD, PhD; Mohammed Nejjari2, MD; Pascal Lim1, MD; Tobias Ruf3, MD; Philipp Blanke4, MD; Ulrich Schäfer5, MD; Hendrik Treede6, MD, PhD; Romain Gallet1, MD, PhD; Julien Dreyfus2, MD
1. Cardiology Department, Henri Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Créteil, France; 2. Cardiology Department, Centre Cardiologique du Nord, Saint-Denis, France; 3. Zentrum für Kardiologie, Universitätsmedizin Mainz, Johannes Gutenberg Universität, Mainz, Germany; 4. Department of Radiology, St Paul's Hospital & University of British Columbia, Vancouver, BC, Canada; 5. Department of Internal Medicine, Marienkrankenhaus, Hamburg, Germany; 6. Department of Cardiac Surgery, University Hospital Mainz, Mainz, Germany
Introduction Severe tricuspid regurgitation (TR) is frequent and associated with poor outcomes1. Nevertheless, many patients are declined for surgery because of prohibitive surgical risks. In this setting, transcatheter tricuspid valve (TV) intervention may be a less invasive option. Transcatheter edge-to-edge repair (TEER) has been the most used approach so far2; however, transcatheter tricuspid valve replacement (TTVR) might be a more attractive strategy. Indeed, besides providing an alterna-tive for patients whose anatomies are not suitable for TEER (due to large coaptation gaps or short/retracted septal leaflets), TTVR procedures are likely to be less challenging and more reproducible, as demonstrated in ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Extracardiac basal annuloplasty for the treatment of secondary mitral regurgitation

Latest news